Ibrutinib dose modifications in the management of CLL

BACKGROUND: Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally included in theclinical trials have additional unfavorable prognostic factors a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy-Abeloos, Camille, Pinotti, Rachel, Gabrilove, Janice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275592/
https://www.ncbi.nlm.nih.gov/pubmed/32503582
http://dx.doi.org/10.1186/s13045-020-00870-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275592/
https://www.ncbi.nlm.nih.gov/pubmed/32503582
http://dx.doi.org/10.1186/s13045-020-00870-w

Ejemplares similares